Family Decision Making in Pediatric Bone Marrow Transplant
儿科骨髓移植中的家庭决策
基本信息
- 批准号:7655312
- 负责人:
- 金额:$ 19.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAllogeneic Bone Marrow TransplantationAllogenicAttentionBenefits and RisksBone MarrowBone Marrow TransplantationChildChildhoodCommunitiesConflict (Psychology)ConsultDataData SourcesDatabasesDecision MakingDescriptorDiseaseEthicsExtended FamilyFamilyFamily ProcessFamily memberFeelingFoundationsFutureGoalsInfectionInjuryInterventionIntervention StudiesInterviewKnowledgeLeadLifeMalignant NeoplasmsMedicalMinorOrgan DonorOutcomePainParentsPatient Self-ReportPatientsPediatric ResearchPerceptionPilot ProjectsPositioning AttributeProceduresProcessProtocols documentationQuestionnairesRegretsResearchRetrospective StudiesRiskRisk AdjustmentSiblingsSiteSolidStressSumTechniquesTestingTimeTranslatingTransplantationValidationbasecourtexperiencehigh riskimprovedpsychologicpublic health relevancerisk perceptionsatisfactiontheoriestherapy design
项目摘要
DESCRIPTION (provided by applicant): Allogeneic bone marrow transplantation (BMT) with a healthy sibling donor is a potentially curative, though life-threatening, treatment for certain high risk pediatric diseases. The decision to proceed with transplant is complicated. The procedure may save the life of the ill child, but subjects the healthy sibling to the physical risks of pain, injury, infection and the psychological burden of feeling responsible for saving the ill sibling. The children are typically minors, so the parents must weigh the risks and benefits for each child , placing them in a conflicted position. If the children are consulted, they are unlikely to refuse given the grave possibility that the ill child may die without treatment. Surprisingly, little is known about how families approach this momentous decision and the risks and benefits they perceive and consider. It is widely assumed by the transplant community and the courts that donor siblings benefit from transplant. However, preliminary pediatric research demonstrates that siblings of children with cancer are at risk for adjustment problems. Further, four retrospective studies suggest that minor donors feel excluded from the decision-making process. The purpose of this four-site, longitudinal pilot study of 18-22 families is to describe, using grounded theory techniques, the experiences of parent/s, patients, donor and non-donor siblings during the decision-making process with attention to their perceptions of benefits and risks. We will develop a substantive theory related to treatment decision- making with the family as our unit of analysis. The specific aims are (1) to develop a data-based, substantive theory of the family decision-making process in families considering an allogeneic bone marrow transplant for a child with cancer using grounded theory techniques; (2) to determine the feasibility of accruing and collecting data from families in which a child is undergoing an allogeneic bone marrow transplant with a minor sibling donor. The goal is to describe the family decision-making process and also to identify factors that may lead to poor outcomes for family members. These data will help guide the design of interventions to improve outcomes for all family members during transplantation. In addition, this study will provide preliminary data to inform the ethical justification for using sibling donors and the regulatory framework for such donation. In sum, this project will provide the firm foundation for a hypothesis- testing large multi-site study that will then translate into an intervention study. PUBLIC HEALTH RELEVANCE: Information on family decision-making about an allogeneic pediatric bone marrow transplant will be applicable to and helpful in designing interventions to improve the outcomes of family decision-making in other pediatric life threatening diseases, and potentially in other high stress family situations. Although, fortunately, life-threatening pediatric diseases are relatively rare, their impact on entire extended families and even communities is immense.
描述(由申请人提供):与健康同胞供体进行异基因骨髓移植(BMT)是一种潜在的治愈性,尽管危及生命,治疗某些高危儿科疾病。进行移植的决定是复杂的。这种手术可以挽救患病儿童的生命,但健康的兄弟姐妹却要承受疼痛、受伤、感染等身体风险,还要承担起拯救患病兄弟姐妹的责任的心理负担。孩子们通常是未成年人,所以父母必须权衡每个孩子的风险和利益,使他们处于矛盾的位置。如果征求儿童的意见,他们不太可能拒绝,因为患病儿童极有可能在不治疗的情况下死亡。令人惊讶的是,人们对家庭如何处理这一重大决定以及他们所感知和考虑的风险和利益知之甚少。移植界和法院普遍认为,捐赠者的兄弟姐妹从移植中受益。然而,初步的儿科研究表明,患有癌症的儿童的兄弟姐妹有适应问题的风险。此外,四项回顾性研究表明,少数捐助者感到被排除在决策过程之外。这个四个站点,纵向试点研究的目的是18-22个家庭的描述,使用扎根理论技术,在决策过程中的父母/s,患者,捐助者和非捐助者的兄弟姐妹的经验,注意他们的利益和风险的看法。我们将发展一个实质性的理论与治疗决策与家庭作为我们的分析单位。具体目标是:(1)使用扎根理论技术,在考虑为癌症儿童进行异基因骨髓移植的家庭中,建立一个基于数据的家庭决策过程的实质性理论;(2)确定从儿童与未成年同胞供体进行异基因骨髓移植的家庭中积累和收集数据的可行性。目的是描述家庭决策过程,并确定可能导致家庭成员不良结果的因素。这些数据将有助于指导干预措施的设计,以改善移植期间所有家庭成员的结果。此外,本研究将提供初步数据,以告知使用同胞供体的伦理理由和此类供体的监管框架。总之,该项目将为假设检验大型多中心研究提供坚实的基础,然后将其转化为干预研究。公共卫生关系:有关异基因儿科骨髓移植的家庭决策信息将适用于并有助于设计干预措施,以改善其他儿科危及生命疾病的家庭决策结果,并可能在其他高压力的家庭情况下。虽然幸运的是,危及生命的儿科疾病相对罕见,但它们对整个大家庭甚至社区的影响是巨大的。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Shared decision-making in pediatric allogeneic blood and marrow transplantation: what if there is no decision to make?
儿科同种异体血液和骨髓移植的共同决策:如果没有决策怎么办?
- DOI:10.1634/theoncologist.2011-0446
- 发表时间:2012
- 期刊:
- 影响因子:0
- 作者:Pentz,RebeccaD;Pelletier,Wendy;Alderfer,MelissaA;Stegenga,Kristin;Fairclough,DianeL;Hinds,PamelaS
- 通讯作者:Hinds,PamelaS
Themes reported by families as important when proceeding with pediatric hematopoietic stem cell transplantation.
家庭报告的主题在进行儿科造血干细胞移植时很重要。
- DOI:10.1002/pbc.25075
- 发表时间:2014
- 期刊:
- 影响因子:3.2
- 作者:Pelletier,Wendy;Hinds,PamelaS;Alderfer,MelissaA;Fairclough,DianeL;Stegenga,Kristin;Pentz,RebeccaD
- 通讯作者:Pentz,RebeccaD
Unmet needs of siblings of pediatric stem cell transplant recipients.
儿科干细胞移植接受者的兄弟姐妹的需求未得到满足。
- DOI:10.1542/peds.2013-3067
- 发表时间:2014
- 期刊:
- 影响因子:8
- 作者:Pentz,RebeccaD;Alderfer,MelissaA;Pelletier,Wendy;Stegenga,Kristin;Haight,AnnE;Hendershot,KristopherA;Dixon,Margie;Fairclough,Diane;Hinds,Pamela
- 通讯作者:Hinds,Pamela
Child and Parent Access to Transplant Information and Involvement in Treatment Decision Making.
儿童和家长获取移植信息并参与治疗决策。
- DOI:10.1177/0193945918770440
- 发表时间:2019
- 期刊:
- 影响因子:1.8
- 作者:Stegenga,Kristin;Pentz,RebeccaD;Alderfer,MelissaA;Pelletier,Wendy;Fairclough,Diane;Hinds,PamelaS
- 通讯作者:Hinds,PamelaS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
REBECCA D PENTZ其他文献
REBECCA D PENTZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('REBECCA D PENTZ', 18)}}的其他基金
Patients' Experiences of Emergency Research (PEER)- Views of Patients included in
紧急研究患者的经历 (PEER) - 纳入患者的观点
- 批准号:
7864202 - 财政年份:2009
- 资助金额:
$ 19.75万 - 项目类别:
Patients' Experiences of Emergency Research (PEER)- Views of Patients included in
紧急研究患者的经历 (PEER) - 纳入患者的观点
- 批准号:
7712208 - 财政年份:2009
- 资助金额:
$ 19.75万 - 项目类别:
Family Decision Making in Pediatric Bone Marrow Transplant
儿科骨髓移植中的家庭决策
- 批准号:
7532253 - 财政年份:2008
- 资助金额:
$ 19.75万 - 项目类别:
Research/Innovative Populations/Craft Ethical Guidelines
研究/创新群体/工艺道德准则
- 批准号:
6795239 - 财政年份:2004
- 资助金额:
$ 19.75万 - 项目类别:
相似海外基金
Chemical Inhibition of SHIP1 To Facilitate Allogeneic Bone Marrow Transplantation
SHIP1 的化学抑制促进同种异体骨髓移植
- 批准号:
8211010 - 财政年份:2011
- 资助金额:
$ 19.75万 - 项目类别:
Chemical Inhibition of SHIP1 To Facilitate Allogeneic Bone Marrow Transplantation
SHIP1 的化学抑制促进同种异体骨髓移植
- 批准号:
8588988 - 财政年份:2011
- 资助金额:
$ 19.75万 - 项目类别:
Chemical Inhibition of SHIP1 To Facilitate Allogeneic Bone Marrow Transplantation
SHIP1 的化学抑制促进同种异体骨髓移植
- 批准号:
8425109 - 财政年份:2011
- 资助金额:
$ 19.75万 - 项目类别:
Chemical Inhibition of SHIP1 To Facilitate Allogeneic Bone Marrow Transplantation
SHIP1 的化学抑制促进同种异体骨髓移植
- 批准号:
8064489 - 财政年份:2011
- 资助金额:
$ 19.75万 - 项目类别:
Influence of the pattern recognition receptor TLR5 on GVHD and the protective effect of donor CD4+CD25+ regulatory T cells following allogeneic bone marrow transplantation
模式识别受体TLR5对GVHD的影响及供者CD4 CD25调节性T细胞对同种异体骨髓移植后的保护作用
- 批准号:
45072841 - 财政年份:2007
- 资助金额:
$ 19.75万 - 项目类别:
Research Units
ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CML
慢性粒细胞白血病(CML)同种异体骨髓移植
- 批准号:
6332459 - 财政年份:2000
- 资助金额:
$ 19.75万 - 项目类别:
ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CML
慢性粒细胞白血病(CML)同种异体骨髓移植
- 批准号:
6203145 - 财政年份:1999
- 资助金额:
$ 19.75万 - 项目类别:
ALLOGENEIC BONE MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY
异体骨髓移植治疗血液恶性肿瘤
- 批准号:
6102092 - 财政年份:1999
- 资助金额:
$ 19.75万 - 项目类别:
Successful allogeneic bone marrow transplantation by injection of bone marrow stromal cells and the cytological and molecular-biological analyses of their role
通过注射骨髓基质细胞成功进行同种异体骨髓移植及其作用的细胞学和分子生物学分析
- 批准号:
11670229 - 财政年份:1999
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving graft-versus-leukemia effect of allogeneic bone marrow transplantation
金属蛋白酶抑制剂可预防急性移植物抗宿主病,同时保留同种异体骨髓移植的移植物抗白血病作用
- 批准号:
11670457 - 财政年份:1999
- 资助金额:
$ 19.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)